Bristol-myers Squibb Compnay

Other

Bristol-myers Company

Bristol Meyers Squibb Company

Bristol-myers Squibb

Bristol-myers

Briston-myers Squibb

Ronald J Mattson

John D Catt

Joseph P Yevich

Daniel J Keavy

Graham Johnson

Michael Frederick Parker

Charles P Sloan

Zhaoxing Meng

Joseph A Cipollina

Dalton King

Katherine S Takaki

David W Smith

Derek John Denhart

Frank D Yocca

John E Macor

Michael A Poss

Lawrence R Marcin

Jonathan L Ditta

Jonas A Gylys

Jeffrey A Deskus

Jun Yuan

Edward H Ruediger

Li-Qiang Sun

Ashok Vinayak Purandare

David R Tortolani

Mendi A Higgins

Gary D Madding

James R Epperson

Robert F Mayol

Joseph L Minielli

Leatte R Guernon

Michael S Eison

Andrew D Williams

Edward C Montgomery

Arlene S Eison

Michael E Brady

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various disorders of the central nervous system. Formula (I): 

Positive allosteric modulators of mGluR2

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various disorders of the central nervous system. 

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders. 

[object Object]

The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts or solvates thereof and pharmaceutically acceptable formulations comprising said compounds useful for the treatment of premature ejaculation, depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder and substance abuse disorders.

Compounds for the treatment of premature ejaculation

Cyclopentyl indole derivatives

Cyclopropylindole derivatives as selective serotonin reuptake inhibitors

Amino-pyrimidine and amino-triazine derivatives having 5-HT antagonist activity for the treatment of sleeping disorders, depression, schizophrenia, anxiety, obsessive compulsive disorders, circadian rhythm disorders, ocular disorders and/or centrally and peripherally mediated hypertension are provided.

5-HT7 receptor antagonists

Antipsychotic heterocycle compounds

Compounds of formula I are useful antidepressant agents

Antidepressant heterocyclic compounds

Novel non-dopaminergic antiischemic compounds have Formula I: ##STR1## wherein R=R.sub.1 and is independently H, C.sub.1-4 alky C.sub.1-4 alkoxy, C.sub.1-4 trihaloalkyl or halogen, or R and R.sub.1 may be taken together to form an --O(CH.sub.2).sub.m O-- (m=1 or 2);

Piperazinyl-cyclohexanes and cyclohexenes

Novel derivatives of benzopyran are provided which are useful as melatonergic agents.

Benzopyran derivatives as melatonergic agents

Novel derivatives of benzodioxa alkylene ethers are provided which are useful as melatonergic agents.

Benzodioxa alkylene ethers as melatonergic agents

Certain N-acyl 2-aryl cyclopropylmethylamine derivatives are useful as melatonergic agents.

N-acyl-2-aryl cyclopropylmethylamine derivatives as melatonergics

Novel derivatives of benzofuran and dihydrobenzofuran are provided which are useful as melatonergic agents.

Benzofuran and dihydrobenzofuran melatonergic agents

Growing community of inventors

Meriden, CT, United States of America

Ronald J Mattson